What did the February 11, 2026 GILD analyst rating updates change?

On February 11, 2026, Scotiabank and Bernstein both maintained **Outperform** on GILD. Scotiabank raised its price target to **$177** and Bernstein to **$160**. The updates reflect higher valuation assumptions, not a switch in overall analyst stance.

How should investors interpret a maintained Outperform in the GILD analyst rating?

A maintained Outperform means analysts still expect GILD to outperform peers. It signals confidence in growth drivers and valuation, but it is not a guarantee. Investors should assess catalysts, pipeline risk, and their time horizon before acting.

Do the new price targets change Gilead’s investment case?

Raised targets to **$177** and **$160** increase implied upside. They matter for valuation, but they do not alter the core investment case. Monitor trial updates, Yeztugo sales, and quarterly guidance to confirm the analyst assumptions.

Where can I find the analyst notes cited in this article on the GILD analyst rating?

Scotiabank’s note was reported by The Fly and Bernstein’s note by StreetInsider. We linked both sources in this article. Use the original reports to review analyst rationale and model assumptions before deciding.

Analyst Ratings

GILD Gilead Sciences: Scotiabank Maintains Outperform, PT $177 Feb 2026

ByDanny Kontos February 12, 2026February 12, 2026

On February 11, 2026, Scotiabank and Bernstein both maintained Outperform on Gilead Sciences, Inc. (GILD). This GILD analyst rating news included Scotiabank raising its price target to $177 from $140, and Bernstein lifting its target to $160. Both firms left their Outperform stance unchanged, signaling continued confidence in Gilead’s pipeline and revenue mix. Investors should note that these are rating confirmations with higher valuation assumptions, not buybacks or guidance changes. Meyka AI provides this report as an AI-powered market analysis platform and Meyka AI rates GILD with a grade of B+. This grade factors in S&P 500 benchmarking, sector performance, financial growth, key metrics, and analyst consensus.